Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol
Y K Onno Teng(Leiden University Medical Center), Paul P. Tak(Celldex Therapeutics (United States)), James Groark(Pfizer (United States)), Robert B. Henderson(Age UK), Ian N Bruce(University of Manchester), Ronald van Vollenhoven(Amsterdam University Medical Centers), Betty Diamond(Feinstein Institute for Medical Research), David Gordon(Universidade Federal de Ouro Preto), Richard Furie(Hofstra University), Mary Oldham(GlaxoSmithKline (United Kingdom))
Cited by 111
Related Papers
NF-κB: a key role in inflammatory diseases
|Journal of Clinical Investigation|2001|3.9k
<i>Consed:</i> A Graphical Tool for Sequence Finishing
|Genome Research|1998|3.3k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women
|New England Journal of Medicine|2005|2k
Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
|New England Journal of Medicine|2018|1.6k